

This application is a continuation of International Application No.

PCT/EP/99/06819 designating the United States, filed September 15, 1999.

IN THE CLAIMS

Cancel claim 13.

Amend claims 1-12 as follows:

1. (Amended) A method for treating or preventing degenerative and/or cancer diseases caused by oxidative processes comprising the administration of a therapeutic amount of a composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative.

2. (Amended) The method according to claim 1 or 14, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative is selected from the group consisting of: tryptophanoctyl-ester, tryptophandodecyl-ester, tryptophanstearyl-ester, tryptophanpalmityl-ester, tryptophanoleyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester, N-palmitoyl-tryptophanethyl-ester and N-oleoyl-tryptophanethyl-ester.

3. (Amended) The method according to claim 1 or 14, wherein the D- or

L-tryptophanethyl-ester or its N-acetyl derivative is selected from the group consisting of tryptophanoctyl-ester, N-oleoyl-tryptophanethyl-ester and N-dodecanoyl-tryptophanethyl-ester.

4. (Amended) The method according to any one of claims 1, 2 or 14, wherein the disease is a neurodegenerative disease.

5. (Amended) The method according to claim 4, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, apoplectic fit or amyotrophic lateral sclerosis.

6. (Amended) The method according to any one of claims 1, 2 or 14, wherein the disease is cataract.

7. (Amended) The method according to claim 6, wherein the cataract is Cataracta senilis, Cataracta juvenilis, Cataracta diabetica or Cataracta complicata.

8. (Amended) The method according to any one of claims 1, 2 or 14, wherein the disease is a neoplastic disease.

9. (Amended) The method according to claim 8, wherein the neoplastic disease is selected from the group consisting of prostatic carcinoma, mammary carcinoma, liver carcinoma, kidney carcinoma, colon carcinoma, gastric carcinoma and lung (bronchial) carcinoma.

10. (Amended) The method according to any one of claims 1, 2 or 14, wherein the disease is a cardiovascular disease.

11. (Amended) The method according to claim 10, wherein the cardiovascular disease is arteriosclerosis or a myocardial infarction.


Sup B1

12. (Amended) A pharmaceutical composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases and, optionally, a pharmaceutically acceptable carrier, alone or in combination with another antioxidatively effective pharmaceutical composition or pharmaceutical composition used with degenerative and/or cancer diseases.

A2

Add claims 14-17 as follows:

14. (Added) The method according to claim 1, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative has the following formula:



wherein X is C(O)R1 or H, and R1 is a saturated C₂-C₁₈ carbon hydrogen residue and R2 is a saturated or unsaturated C₂-C₁₈ carbon hydrogen residue.

15. (Added) The pharmaceutical composition according to claim 12, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative has the following formula:

